Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
Open Access
- 1 March 2017
- journal article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 4, 126-136
Abstract
No abstract availableKeywords
Funding Information
- NIH (R01AR065873)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Genethon
This publication has 39 references indexed in Scilit:
- Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERTPLOS ONE, 2013
- Immunodominant Liver-Specific Expression Suppresses Transgene-Directed Immune Responses in Murine Pompe DiseaseHuman Gene Therapy, 2012
- Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry RegistryMolecular Genetics and Metabolism, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapyBlood, 2010
- Treatment of hemophilia: a review of current advances and ongoing issuesJournal of Blood Medicine, 2010
- Immunomodulatory Gene Therapy Prevents Antibody Formation and Lethal Hypersensitivity Reactions in Murine Pompe DiseaseMolecular Therapy, 2010
- Immune response hinders therapy for lysosomal storage diseasesJournal of Clinical Investigation, 2008
- Enhanced Response to Enzyme Replacement Therapy in Pompe Disease after the Induction of Immune ToleranceThe American Journal of Human Genetics, 2007
- High Levels of Persistent Expression of α1-Antitrypsin Mediated by the Nonhuman Primate Serotype rh.10 Adeno-associated Virus Despite Preexisting Immunity to Common Human Adeno-associated VirusesMolecular Therapy, 2006